ImmunoGenesis, a clinical-stage biotechnology company developing immune therapies, has appointed seasoned industry veterans to key roles to support the expansion of the company's R&D, clinical and business development activities.
ProBioGen AG today announced that Immunogenesis, Inc., a spin-off of the MD Anderson Cancer Center, University of Texas, has signed a Service Agreement for Cell Line Development, Process Development and GMP Manufacturing in 1,000 L bioreactor scale for th